418 related articles for article (PubMed ID: 25670862)
1. Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion.
Nolan KD; Franco OE; Hance MW; Hayward SW; Isaacs JS
J Biol Chem; 2015 Mar; 290(13):8271-82. PubMed ID: 25670862
[TBL] [Abstract][Full Text] [Related]
2. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer.
Hance MW; Dole K; Gopal U; Bohonowych JE; Jezierska-Drutel A; Neumann CA; Liu H; Garraway IP; Isaacs JS
J Biol Chem; 2012 Nov; 287(45):37732-44. PubMed ID: 22989880
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia induces TWIST-activated epithelial-mesenchymal transition and proliferation of pancreatic cancer cells in vitro and in nude mice.
Chen S; Chen JZ; Zhang JQ; Chen HX; Yan ML; Huang L; Tian YF; Chen YL; Wang YD
Cancer Lett; 2016 Dec; 383(1):73-84. PubMed ID: 27693633
[TBL] [Abstract][Full Text] [Related]
4. Secreted heat shock protein 90 promotes prostate cancer stem cell heterogeneity.
Nolan KD; Kaur J; Isaacs JS
Oncotarget; 2017 Mar; 8(12):19323-19341. PubMed ID: 28038472
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2.
Ma DN; Chai ZT; Zhu XD; Zhang N; Zhan DH; Ye BG; Wang CH; Qin CD; Zhao YM; Zhu WP; Cao MQ; Gao DM; Sun HC; Tang ZY
J Hematol Oncol; 2016 Jan; 9():1. PubMed ID: 26733151
[TBL] [Abstract][Full Text] [Related]
6. Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM
Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826
[TBL] [Abstract][Full Text] [Related]
7. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
8. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin.
Tong ZT; Cai MY; Wang XG; Kong LL; Mai SJ; Liu YH; Zhang HB; Liao YJ; Zheng F; Zhu W; Liu TH; Bian XW; Guan XY; Lin MC; Zeng MS; Zeng YX; Kung HF; Xie D
Oncogene; 2012 Feb; 31(5):583-94. PubMed ID: 21685935
[TBL] [Abstract][Full Text] [Related]
9. EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity.
Chang JW; Gwak SY; Shim GA; Liu L; Lim YC; Kim JM; Jung MG; Koo BS
Oral Oncol; 2016 Jan; 52():66-74. PubMed ID: 26604082
[TBL] [Abstract][Full Text] [Related]
10.
Terashima M; Ishimura A; Wanna-Udom S; Suzuki T
J Biol Chem; 2018 Nov; 293(47):18016-18030. PubMed ID: 30262664
[TBL] [Abstract][Full Text] [Related]
11. Mutations and deletions of PRC2 in prostate cancer.
Jain P; Di Croce L
Bioessays; 2016 May; 38(5):446-54. PubMed ID: 27000413
[TBL] [Abstract][Full Text] [Related]
12. Loss of TET1 facilitates DLD1 colon cancer cell migration via H3K27me3-mediated down-regulation of E-cadherin.
Zhou Z; Zhang HS; Liu Y; Zhang ZG; Du GY; Li H; Yu XY; Huang YH
J Cell Physiol; 2018 Feb; 233(2):1359-1369. PubMed ID: 28513825
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
14. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer.
Ding M; Zhang H; Li Z; Wang C; Chen J; Shi L; Xu D; Gao Y
Clin Exp Pharmacol Physiol; 2015 May; 42(5):458-64. PubMed ID: 25739318
[TBL] [Abstract][Full Text] [Related]
15. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.
Liu L; Xu Z; Zhong L; Wang H; Jiang S; Long Q; Xu J; Guo J
BJU Int; 2016 Feb; 117(2):351-62. PubMed ID: 24612432
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic suppression of E-cadherin expression by Snail2 during the metastasis of colorectal cancer.
Hu Y; Dai M; Zheng Y; Wu J; Yu B; Zhang H; Kong W; Wu H; Yu X
Clin Epigenetics; 2018 Dec; 10(1):154. PubMed ID: 30541610
[TBL] [Abstract][Full Text] [Related]
17. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming.
Tiwari N; Tiwari VK; Waldmeier L; Balwierz PJ; Arnold P; Pachkov M; Meyer-Schaller N; Schübeler D; van Nimwegen E; Christofori G
Cancer Cell; 2013 Jun; 23(6):768-83. PubMed ID: 23764001
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing.
Jiang FZ; He YY; Wang HH; Zhang HL; Zhang J; Yan XF; Wang XJ; Che Q; Ke JQ; Chen Z; Tong H; Zhang YL; Wang FY; Li YR; Wan XP
Oncotarget; 2015 Dec; 6(42):44660-74. PubMed ID: 26587974
[TBL] [Abstract][Full Text] [Related]
19. MEG3 Long Noncoding RNA Contributes to the Epigenetic Regulation of Epithelial-Mesenchymal Transition in Lung Cancer Cell Lines.
Terashima M; Tange S; Ishimura A; Suzuki T
J Biol Chem; 2017 Jan; 292(1):82-99. PubMed ID: 27852821
[TBL] [Abstract][Full Text] [Related]
20. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
